Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HEIDI A MCKEAN

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1992714281
CMS profile
419958
Location
SIOUX FALLS, SD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$77.19

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $62.00 1
Food and Beverage $15.19 1

By paying entity

PY2023 · entire year · sorted by reported total

Paying entityAmountRecords
Eisai Inc. $62.00 1
Amgen Inc. $15.19 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HEIDI A MCKEAN

NPI 1992714281 · CMS profile ID 419958

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

SIOUX FALLS, SD

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1992714281?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HEIDI A MCKEAN, NPI 1992714281, CMS profile ID 419958. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1992714281?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). HEIDI A MCKEAN, NPI 1992714281, CMS profile ID 419958. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1992714281?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
HEIDI A MCKEAN, NPI 1992714281, CMS profile ID 419958, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1992714281?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $77.19 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $15.1907/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019925209 CMS
Eisai Inc. $62.0002/06/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1053715685 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $20.74 1
PY2020 $67.75 1
PY2021 $145.87 8
PY2022 $14.13 1
PY2023 $77.19 2
PY2025 $226.47 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $621,755.28 64
PY2024 Principal investigator $670,932.23 24
PY2023 Principal investigator $188,869.75 16
PY2022 Principal investigator $191,521.33 17
PY2021 Principal investigator $269,453.84 10
PY2020 Principal investigator $41,893.57 9
PY2019 Principal investigator $58,617.55 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

64 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $733.80 12/31/2025 Covered Recipient Teaching Hospital
Avera Mckennan
A Phase 2a Study with Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1232932483
Principal investigator 1 Boehringer Ingelheim International GmbH $509.10 12/17/2025 Non-covered Recipient Entity
Avera Medical Group Oncology And Hematology Public Health Service Outpatient
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220642580
Principal investigator 1 Boehringer Ingelheim International GmbH $139.92 12/17/2025 Non-covered Recipient Entity
Avera Medical Group Oncology And Hematology Public Health Service Outpatient
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220642582
Principal investigator 1 Boehringer Ingelheim International GmbH $539.46 12/17/2025 Non-covered Recipient Entity
Avera Medical Group Oncology And Hematology Public Health Service Outpatient
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220642584
Principal investigator 1 Boehringer Ingelheim International GmbH $292.00 12/17/2025 Non-covered Recipient Entity
Avera Medical Group Oncology And Hematology Public Health Service Outpatient
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220642586
Principal investigator 1 Boehringer Ingelheim International GmbH $244.28 12/17/2025 Non-covered Recipient Entity
Avera Medical Group Oncology And Hematology Public Health Service Outpatient
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220642588
Principal investigator 1 Boehringer Ingelheim International GmbH $5.68 12/17/2025 Non-covered Recipient Entity
Avera Medical Group Oncology And Hematology Public Health Service Outpatient
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220642590
Principal investigator 1 Boehringer Ingelheim International GmbH $143.00 12/17/2025 Non-covered Recipient Entity
Avera Medical Group Oncology And Hematology Public Health Service Outpatient
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220642592
Principal investigator 1 Boehringer Ingelheim International GmbH $30.66 12/17/2025 Non-covered Recipient Entity
Avera Medical Group Oncology And Hematology Public Health Service Outpatient
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220642594
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 12/17/2025 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223263838
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $800.00 12/17/2025 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223263840
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,000.00 12/17/2025 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223263842
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $56.70 12/17/2025 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223263844
Principal investigator 1 Boehringer Ingelheim International GmbH $150.00 12/08/2025 Non-covered Recipient Entity
Avera Medical Group Oncology And Hematology Public Health Service Outpatient
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220642576
Principal investigator 1 ABBVIE INC. $2,499.74 12/05/2025 Covered Recipient Teaching Hospital
AVERA MCKENNAN
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202404680
Principal investigator 1 ABBVIE INC. $2,601.38 12/04/2025 Covered Recipient Teaching Hospital
AVERA MCKENNAN
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202404676
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
Avera Medical Group Oncology And Hematology Public Health Service Outpatient
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220642578
Principal investigator 1 ABBVIE INC. $6,368.04 11/13/2025 Covered Recipient Teaching Hospital
AVERA MCKENNAN
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202404670
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
Avera Medical Group Oncology And Hematology Public Health Service Outpatient
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) alone or in combination with other agents for the treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) No dispute reported 06/30/2026 1220642574
Principal investigator 1 ABBVIE INC. $3,300.00 09/25/2025 Covered Recipient Teaching Hospital
AVERA MCKENNAN
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202404663
Principal investigator 1 ABBVIE INC. $3,350.01 09/25/2025 Covered Recipient Teaching Hospital
AVERA MCKENNAN
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil Folinic Acid and Bevacizumab No dispute reported 06/30/2026 1202404666
Principal investigator 1 PFIZER INC. $7,969.40 09/22/2025 Non-covered Recipient Entity
Avera Cancer Institute
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228717701
Principal investigator 1 PFIZER INC. $10,940.00 09/22/2025 Non-covered Recipient Entity
Avera Cancer Institute
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228717825
Principal investigator 1 PFIZER INC. $32,997.51 09/22/2025 Non-covered Recipient Entity
Avera Cancer Institute
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228717827
Principal investigator 1 PFIZER INC. $7,969.40 09/19/2025 Non-covered Recipient Entity
Avera Cancer Institute
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228716801
Principal investigator 1 PFIZER INC. $10,940.00 09/19/2025 Non-covered Recipient Entity
Avera Cancer Institute
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228716973
Principal investigator 1 PFIZER INC. $32,997.51 09/19/2025 Non-covered Recipient Entity
Avera Cancer Institute
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228716975
Principal investigator 1 GlaxoSmithKline, LLC. $4,353.99 09/16/2025 Non-covered Recipient Entity
AVERA MCKENNAN
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192168263
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $9,820.20 08/13/2025 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223263820
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,732.90 08/13/2025 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223263822
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 07/24/2025 Non-covered Recipient Entity
AVERA MCKENNAN
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192165185
Principal investigator 1 GlaxoSmithKline, LLC. $1,368.38 07/21/2025 Non-covered Recipient Entity
AVERA MCKENNAN
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192165181
Principal investigator 1 GlaxoSmithKline, LLC. $11,215.04 07/21/2025 Non-covered Recipient Entity
AVERA MCKENNAN
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192168260
Principal investigator 1 ABBVIE INC. $750.00 07/08/2025 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202404659
Principal investigator 1 GlaxoSmithKline, LLC. $6,660.98 06/13/2025 Non-covered Recipient Entity
AVERA MCKENNAN
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192168256
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $90,545.00 06/04/2025 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223263814
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,551.00 06/04/2025 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223263816
Principal investigator 1 GlaxoSmithKline, LLC. $1,427.66 05/28/2025 Non-covered Recipient Entity
AVERA CANCER INSTITUTE AT SIOUX FALLS
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192168276
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,025.40 05/23/2025 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223263812
Principal investigator 1 GlaxoSmithKline, LLC. $11,530.59 05/14/2025 Non-covered Recipient Entity
AVERA MCKENNAN
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192165193
Principal investigator 1 Merck Sharp & Dohme LLC $124,200.00 05/02/2025 Covered Recipient Teaching Hospital
Avera Mckennan
A Phase 2a Study with Safety Run-in to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FF-10832 Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1232932531
Principal investigator 1 GlaxoSmithKline, LLC. $1,652.43 04/28/2025 Non-covered Recipient Entity
AVERA MCKENNAN
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192165189
Principal investigator 1 GlaxoSmithKline, LLC. $3,208.53 04/28/2025 Non-covered Recipient Entity
AVERA MCKENNAN
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192168249
Principal investigator 1 PFIZER INC. $10,940.00 04/16/2025 Non-covered Recipient Entity
Avera Cancer Institute
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228754734
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,177.40 04/16/2025 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223263810
Principal investigator 1 PFIZER INC. $10,940.00 04/14/2025 Non-covered Recipient Entity
Avera Cancer Institute
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228756519
Principal investigator 1 GlaxoSmithKline, LLC. $9,274.86 04/09/2025 Non-covered Recipient Entity
AVERA MCKENNAN
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192168272
Principal investigator 1 GlaxoSmithKline, LLC. $10,173.31 03/21/2025 Non-covered Recipient Entity
AVERA MCKENNAN
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192168267
Principal investigator 1 GlaxoSmithKline, LLC. $7,234.30 03/21/2025 Non-covered Recipient Entity
AVERA MCKENNAN
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY OF PERIOPERATIVE DOSTARLIMAB M No dispute reported 06/30/2026 1192168280
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $11,177.40 03/19/2025 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223263798
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $8,671.00 03/19/2025 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223263800
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 03/19/2025 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223263802
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,050.00 03/19/2025 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223263804
Principal investigator 1 ABBVIE INC. $21,750.00 03/11/2025 Covered Recipient Teaching Hospital
AVERA MCKENNAN
M24-064 - A Randomized Trial Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Over-Expressed Refractory Metastatic Colorectal Cancer No dispute reported 06/30/2026 1202404655
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,000.00 02/17/2025 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A PHASE 1, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, SAFETY, IMMUNOGENICITY, AND DOSE RANGING STUDY OF PURIFIED INACTIVATED ZIKA VIRUS VACCINE (PIZV) CANDIDATE IN FLAVIVIRUS NA?VE AND PRIMED HEALTHY ADULTS AGED 18 TO 49 YEARS No dispute reported 06/30/2026 1223263796
Principal investigator 1 PFIZER INC. $32,997.51 02/04/2025 Non-covered Recipient Entity
Avera Cancer Institute
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228754855
Principal investigator 1 PFIZER INC. $32,997.51 02/03/2025 Non-covered Recipient Entity
Avera Cancer Institute
AN OPENLABEL RANDOMIZED PHASE 3 STUDY OF TUCATINIB IN COMBINATION WITH TRASTUZUMAB AND MFOLFOX6 VERSUS MFOLFOX6 GIVEN WITH OR WITHOUT EITHER CETUXIMAB OR BEVACIZUMAB AS FIRSTLINE TREATMENT FOR SUBJECTS WITH HER2 METASTATIC COLORECTAL CANCER No dispute reported 06/30/2026 1228719977
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $13,202.80 01/22/2025 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223263786
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,127.00 01/22/2025 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223263788
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $864.50 01/22/2025 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A PHASE 1/2, FIRST-IN-HUMAN, OPEN LABEL, DOSE ESCALATION STUDY OF MVC-101, AN EGFR X CD3 CONDITIONAL BISPECIFIC REDIRECTED ACTIVATION (COBRATM) PROTEIN IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC CANCER No dispute reported 06/30/2026 1223263790
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,000.00 01/17/2025 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A PHASE 1, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, SAFETY, IMMUNOGENICITY, AND DOSE RANGING STUDY OF PURIFIED INACTIVATED ZIKA VIRUS VACCINE (PIZV) CANDIDATE IN FLAVIVIRUS NA?VE AND PRIMED HEALTHY ADULTS AGED 18 TO 49 YEARS No dispute reported 06/30/2026 1223263778
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,000.00 01/17/2025 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A PHASE 1, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, SAFETY, IMMUNOGENICITY, AND DOSE RANGING STUDY OF PURIFIED INACTIVATED ZIKA VIRUS VACCINE (PIZV) CANDIDATE IN FLAVIVIRUS NA?VE AND PRIMED HEALTHY ADULTS AGED 18 TO 49 YEARS No dispute reported 06/30/2026 1223263780
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,000.00 01/17/2025 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A PHASE 1, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, SAFETY, IMMUNOGENICITY, AND DOSE RANGING STUDY OF PURIFIED INACTIVATED ZIKA VIRUS VACCINE (PIZV) CANDIDATE IN FLAVIVIRUS NA?VE AND PRIMED HEALTHY ADULTS AGED 18 TO 49 YEARS No dispute reported 06/30/2026 1223263782
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $5,000.00 01/17/2025 Covered Recipient Teaching Hospital
AVERA MCKENNAN
A PHASE 1, RANDOMIZED, OBSERVER-BLIND, PLACEBO-CONTROLLED, SAFETY, IMMUNOGENICITY, AND DOSE RANGING STUDY OF PURIFIED INACTIVATED ZIKA VIRUS VACCINE (PIZV) CANDIDATE IN FLAVIVIRUS NA?VE AND PRIMED HEALTHY ADULTS AGED 18 TO 49 YEARS No dispute reported 06/30/2026 1223263784